RESUMO
Metabolic syndrome is a disease the World Health Organization has called a new pandemic of the 21st century. Arterial hypertension is one of the criteria for this diagnosis and a determinant of damage to major target organs. The present clinical case demonstrates an experience of treatment of arterial hypertension associated with metabolic syndrome with a valsartan/sacubitril molecular complex.
Assuntos
Insuficiência Cardíaca , Hipertensão , Síndrome Metabólica , Aminobutiratos/uso terapêutico , Antagonistas de Receptores de Angiotensina/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Compostos de Bifenilo/farmacologia , Compostos de Bifenilo/uso terapêutico , Pressão Sanguínea , Método Duplo-Cego , Combinação de Medicamentos , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Hipertensão/complicações , Hipertensão/diagnóstico , Hipertensão/tratamento farmacológico , Síndrome Metabólica/tratamento farmacológico , Volume Sistólico , Tetrazóis/uso terapêutico , Valsartana/uso terapêuticoRESUMO
AIM: In real life to evaluate the effectiveness and safety of apixaban with double antiplatelet therapy for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and the recent episode of acute coronary syndrome without ST segment elevation. MATERIALS AND METHODS: 8 patients with atrial fibrillation and the recent (8-14 days after the onset of symptoms of ACS) episode of acute coronary syndrome without ST segment elevation were involved into the research. The effectiveness (deaths, stroke and systemic embolism) and the safety (major clinically significant and not significant bleeding) were investigated within 3 months. RESULTS: There were no any strokes, systemic embolism, deaths during observational period. Nasal and mild gingival hemorrhages (not requiring medical intervention) were noted in 2 patients during the first month of treatment and two patients experienced non-permanent petechiae. Major and clinically significant bleeding was not registered. onclusions: the use of oral anticoagulant apixaban 5 mg BID or 2.5 mg BID with double antiplatelet therapy in patients with non-valvular atrial fibrillation and the recent episode of acute coronary syndrome without ST segment elevation is effective and safe for the prevention of stroke and systemic embolism during 3 months of treatment. Future researches are required.
Assuntos
Síndrome Coronariana Aguda/complicações , Síndrome Coronariana Aguda/tratamento farmacológico , Fibrilação Atrial/complicações , Fibrilação Atrial/tratamento farmacológico , Inibidores do Fator Xa/uso terapêutico , Fibrinolíticos/uso terapêutico , Pirazóis/uso terapêutico , Piridonas/uso terapêutico , Administração Oral , Idoso , Quimioterapia Combinada , Feminino , Humanos , Masculino , Acidente Vascular Cerebral/prevenção & controleRESUMO
Some inflammatory cytokines and parameters of low density lipoproteins (LDL) oxidative modification were studied in blood of 250 acute coronary syndrome (ACS) patients--Siberian inhabitants, men and women with myocardial infarction (MI) or unstable angina on first, tenth and thirtieth days of disease. The inflammatory biomarkers in men and women with MI are: increased concentrations of interleukin (IL)-6, IL-8 and C-reactive protein (CRP), especially on the first day of disease. The most significant inflammatory biomarker of ACS is increased CRP level, especially in women. Oxidative biomarkers in men with ACS are increased basal level of LDL lipid peroxidation (LPO) products and decreased LDL resistance to oxidation. Inflammatory-oxidative biomarkers IL-6, IL-8, CRP and basal level of LDL LPO products are correlated and independently associated with MI.
